Brii Biosciences

Brii Biosciences (腾盛博药) is a clinical-stage biopharmaceutical company founded in China with a focus on infectious diseases and central nervous system (CNS) disorders. The company was established to bring together drug candidates from international partners and advance them through clinical development in China and globally, with a portfolio that has included programs in hepatitis B, HIV, multi-drug-resistant infections, postpartum depression and COVID-19. The company is best known publicly for its COVID-19 neutralizing antibody combination therapy, which was developed with partners including Tsinghua University and The 3rd People's Hospital of Shenzhen and received regulatory approval in China in 2021 — one of the first domestically developed COVID-19 antibody treatments to reach the market there. Brii has also worked on hepatitis B functional cure candidates and CNS assets licensed from global biotech partners. Brii Biosciences is listed on the Hong Kong Stock Exchange under the ticker 2137.HK, having completed its IPO in 2021. It operates as a China-rooted but globally oriented biotech, with research and business operations spanning China and the United States, and it positions itself as a bridge for innovative therapies between Western biotech innovators and the Chinese market. Like many clinical-stage Chinese biotechs, the company's commercial profile has been shaped by the shifting COVID-19 landscape, the Chinese regulatory environment for innovative drugs, and the broader funding climate for unprofitable biotech listings. Its strategy centers on differentiated assets in areas of high unmet need, particularly infectious disease and CNS, rather than on large-scale generic manufacturing.

Brii Biosciences was founded in 2018 as a China-based biopharmaceutical company with a model of in-licensing and co-developing drug candidates from international partners and advancing them in China and globally. Its founding leadership combined experience in global pharma and Chinese biotech, and the company set up operations in China and the United States. The company's pipeline was built around infectious diseases — notably hepatitis B, HIV and multi-drug-resistant bacterial infections — and central nervous system disorders. Brii licensed assets from partners in the United States and elsewhere, aiming to bridge innovative Western science into the Chinese clinical and regulatory system. Brii rose to public prominence during the COVID-19 pandemic. Working with Tsinghua University and The 3rd People's Hospital of Shenzhen, it developed a neutralizing antibody combination (amubarvimab/romlusevimab) that received emergency approval in China in December 2021, making it one of the first domestically developed COVID-19 antibody therapies approved there. The therapy was later used in China and also pursued international regulatory pathways. In 2021 Brii Biosciences completed an initial public offering on the Hong Kong Stock Exchange (ticker 2137.HK), joining a wave of pre-revenue Chinese biotech listings enabled by Hong Kong's biotech listing regime. Proceeds were directed toward clinical development of its pipeline. After the peak of the COVID-19 pandemic, demand for antibody therapies fell sharply, and the company refocused on its hepatitis B functional cure programs and CNS assets. Its later history has been shaped by the broader downturn in biotech financing, pipeline prioritization decisions, and partnership activity typical of clinical-stage Chinese biotechs.

• 2021

  Completes IPO on the Hong Kong Stock Exchange (ticker 2137.HK).

• 2021

  Its COVID-19 neutralizing antibody combination receives approval in China.

• 2018

  Brii Biosciences is founded as a China-based biopharmaceutical company.

A China-rooted, globally oriented clinical-stage biotech focused on infectious disease and CNS therapies with high unmet need.

• Amubarvimab/romlusevimab COVID-19 antibody combination

• Hepatitis B functional cure programs

• CNS pipeline

• 2026

  Brii Biosciences discloses central lab test kit recall affecting ENHANCE trial HBsAg data

  Brii Biosciences announced that on August 19, 2026, it received an email notice from a central laboratory service provider regarding a recall of a commercially available test kit batch (Roche Elecsys HBsAg II quant II) used for HBsAg testing in the ENHANCE study. The company stated that the potential impact on its published clinical trial data appears limited to the end-of-treatment HBsAg data from ENHANCE Part A-2, and that it is working with the provider to identify affected samples and arrange retesting with unaffected kits.

  Source

Read more

• 2026-08-19

  Brii Biosciences discloses central lab test kit recall affecting ENHANCE trial HBsAg data[1]Brii Biosciences discloses central lab test kit recall affecting ENHANCE trial HBsAg dataprnasia.com

  Reported: 2026-08-20

  Brii Biosciences announced that on August 19, 2026, it received an email notice from a central laboratory service provider regarding a recall of a commercially available test kit batch (Roche Elecsys HBsAg II quant II) used for HBsAg testing in the ENHANCE study. The company stated the potential impact on its published clinical trial data appears limited to the end-of-treatment HBsAg data from ENHANCE Part A-2, and it is working with the provider to identify affected samples and arrange retesting with unaffected kits.

• 2021-11-17

  Brii Biosciences wins 2021 Research Achievement award[2]腾盛博药荣获2021年度研发成就奖prnasia.com

  Reported: 2021-11-17

  Brii Biosciences announced that it received the BioCentury-BayHelix “2021 R&D Achievement” Award, which recognized the company’s achievements in developing the BRII-196/BRII-198 combination therapy.

1. 1Brii Biosciences discloses central lab test kit recall affecting ENHANCE trial HBsAg dataprnasia.com
2. 2腾盛博药荣获2021年度研发成就奖prnasia.com